{
    "clinical_study": {
        "@rank": "70640", 
        "arm_group": {
            "arm_group_label": "RRx-001", 
            "arm_group_type": "Experimental", 
            "description": "RRx-001 will be administered as subcutaneous injections twice weekly for at least 8 weeks. At least three subjects must complete 2 weeks of treatment with RRx-001 at each dose level, before escalation to the next higher RRx-001 dose level; 2 doses\u201416 and 27 mg/m2\u2014 will be tested."
        }, 
        "brief_summary": {
            "textblock": "To investigate the dosage of RRx-001 by the subcutaneous route."
        }, 
        "brief_title": "A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Malignant Solid Tumor", 
            "Lymphomas"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase I, open-label, dose-escalation study of RRx-001. Subjects will receive\n      RRx-001 administered as subcutaneous injections twice weekly for at least 8 weeks. At least\n      three subjects must complete 2 weeks of treatment with RRx-001 at each dose level, before\n      escalation to the next higher RRx-001 dose level; 2 doses\u201416 and 27 mg/m2\u2014 will be tested.\n\n      The purpose of the study is to extend the dosage options for RRx-001 since faster\n      subcutaneous (SC) administration may increase convenience versus the traditional IV method.\n      The study also will also measure the mean concentrations of an RRx-001 metabolite in the\n      blood (pharmacokinetics; PK) versus the IV formulation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years old.\n\n          -  ECOG (performance) status of 0, 1 or 2.\n\n          -  Histologically or cytologically confirmed primary or metastatic advanced solid tumors\n             or lymphoma. Subjects with curative treatment options are not eligible for the\n             protocol.\n\n          -  No active ongoing cancer treatment (except for prostate cancer subjects receiving\n             luteinizing hormone-releasing hormone (LHRH) agonists and anti-androgens such as;\n             Flutamide, Dutasteride, and Finasteride).\n\n          -  Adequate organ and bone marrow function.\n\n          -  Male and female subjects of childbearing potential must agree to use contraception.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding.\n\n          -  Use of anti-coagulant therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096341", 
            "org_study_id": "RRx001-12-01"
        }, 
        "intervention": {
            "arm_group_label": "RRx-001", 
            "description": "RRx-001 Dose level 1 (16 mg/m2) twice weekly\nRRx-001 Dose level 2 (27 mg/m2) twice weekly", 
            "intervention_name": "RRx-001", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 21, 2014", 
        "link": {
            "description": "RadioRx, Inc Home page.", 
            "url": "http://www.radiorx.com/"
        }, 
        "location": [
            {
                "contact": {
                    "email": "hlien@gcrioncology.com", 
                    "last_name": "Leilani H Lien, BSH, RN, PHN", 
                    "phone": "408-384-9284"
                }, 
                "facility": {
                    "address": {
                        "city": "San Jose", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95124"
                    }, 
                    "name": "Global Cancer Research Institute"
                }, 
                "investigator": {
                    "last_name": "Lynne Bui, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Heather.Pedigo@scresearch.net", 
                    "last_name": "Heather Pedigo", 
                    "phone": "615-329-7274"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Infante, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001", 
        "overall_contact": {
            "email": "info@radiorx.com", 
            "last_name": "Bryan Oronsky, MD", 
            "phone": "650.943.2426"
        }, 
        "overall_contact_backup": {
            "email": "info@radiorx.com", 
            "last_name": "Jan Scicinski, PhD", 
            "phone": "650.943.2426"
        }, 
        "overall_official": [
            {
                "affiliation": "Global Cancer Research Institute", 
                "last_name": "Lynne Bui, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "SCRI Development Innovations, LLC", 
                "last_name": "Jeffrey Infante, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with Serious and Non-Serious Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "10 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096341"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the plasma concentration versus time curve (AUC) of RRx-001-glutathione conjugate", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "measure": "Peak Plasma Concentration (Cmax) of RRx-001-glutathione conjugate", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }
        ], 
        "source": "RadioRx, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RadioRx, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}